-
Mashup Score: 2Case Series of Men with the Germline APC I1307K Variant and Treatment-Emergent Neuroendocrine Prostate Cancer - Beyond the Abstract - 6 day(s) ago
prostate cancer, Germline APC I1307K mutation, androgen receptor signaling pathway, Treatment-Emergent Neuroendocrine Prostate Cancer, aggressive variant prostate cancer (AVPC), RB1, TP53, PTEN.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: A. Oliver Sartor, MD, Disease Group Leader GU Cancers, Director of Radiopharmaceutical Trials, Mayo Clinic, Rochester, MN Neal D. Shore, MD, FACS, Medical Director, Carolina Urologic Research Center, Atlantic Urology…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 3Broadening Treatment Horizons with CDK4/6 Inhibitors from Breast to Prostate Cancer - Rana McKay - 6 day(s) ago
Program: Beyond Androgen Blockade – New Pathways and Novel Treatments in mHSPC and mCRPC Part of an Independent Medical Education Initiative Supported by LOXO@Lilly Biographies: Rana R. McKay, Medical Oncologist, Associate Professor, University of California, San Diego, San Diego, CA Alicia Morgans, MD, MPH , Genitourinary Medical Oncologist, Medical Director of Survivorship Program at…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 19
A single invitation for PSA screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years.
Source: prostate.uroonco.uroweb.orgCategories: General Medicine News, UrologyTweet
-
Mashup Score: 16ENZA-p Trial Shows Promise for Enzalutamide-Lutetium Combination in Prostate Cancer - Louise Emmett - 10 day(s) ago
Alicia Morgans speaks with Louise Emmett about the ENZA-p study, presented at ESMO 2023. This groundbreaking research explores the combination of lutetium and enzalutamide in treating early metastatic castrate-resistant prostate cancer. Patients, previously showing limited response to enzalutamide, were screened with PSMA PET and randomized to receive either enzalutamide alone or combined with…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
Andrea Miyahira hosts Ping Mu to discuss his group’s research on prostate cancer resistance to anti-androgens. Dr. Mu’s study, published in Oncogene, focuses on the gene UBE2J1, identified as a key E2 ubiquitin-conjugating enzyme regulating Androgen Receptor (AR) degradation. He explains that despite advancements in anti-androgen therapies like enzalutamide, resistance remains a significant…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 2Identification of genes that promote PI3K pathway activation and prostate tumour formation - 10 day(s) ago
Oncogene – Identification of genes that promote PI3K pathway activation and prostate tumour formation
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 18
prostate cancer, PARP Inhibitor Therapy, Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, PARP inhibitors, androgen receptor pathway inhibitor (ARPI), homologous recombination repair (HRR) genes, Olaparib plus Radium-223, Olaparib, Radium-223, Niraparib, abiraterone, enzalutamide, Talazoparib, Niraparib plus abiraterone, Talazoparib plus enzalutamide, COMRADE trial, BRCA1/2 alterations, KEYNOTE-365 study, Pembrolizumab, Durvalumab, avelumab, Bipolar Androgen Therapy (BAT), supraphysiologic testosterone (SPT), Cediranib, Olaparib plus Cediranib, Rad3-related protein (ATR) inhibitor, ceralasterib, TRAP trial, KEYLYNK-010 Trial, JAVELIN PARP Medley trial,
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0
Patient/provider trust, education and lifestyle choices are crucial as Black men face higher incidence and mortality in prostate cancer, experts said.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 0Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer - 11 day(s) ago
This segment delves into targeting the androgen receptor pathway and conquering treatment resistance for potential breakthroughs in managing advanced prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Case series explores the link between germline APC I1307K variant and treatment-emergent neuroendocrine #ProstateCancer. Discoveries shed light on potential genetic predictors & underline the need for personalized surveillance strategies > https://t.co/CC7Jm3VGpW @minaseconomides https://t.co/9zhksZ7adz